Sun Pharmaceutical Industries announced a licensing deal with Takeda Pharmaceutical to market Vonoprazan, a novel gastrointestinal drug, in India. The agreement allows Sun Pharma to commercialize 10 mg and 20 mg tablets of Vonoprazan, an innovative treatment for acid peptic disorders, under a non-exclusive patent license. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
